Presentation of Q3 2022 financial results

1. Our exceptional results for
the third quarter demonstrate
that Sanofi is on the right path.
We delivered remarkable sales growth
and our commitment to breakthrough
science is bearing fruit as we achieved
key regulatory milestones for three of
our priority medicines.
Paul Hudson
Chief Executive Officer, Sanofi
Q3 2022 results
Company sales and business EPS*
Sales by global business unit
Sales by geography
** Growth rates are expressed at constant exchange rates (CER).
Growth rates in parentheses are expressed on a reported basis.
Q3 2022
company sales**
€12,482m
+9.0% (+19.7%)
€2.88
+17.9% (+32.1%)
* Earnings per share
Q3 2022
business EPS**
€2,596m
Europe
€6,042m
US
€3,844m
Rest of
the World
For further information on Q3 2022 results
and definitions of financial indicators, please refer
to the press release issued on October 28, 2022 at:
www.sanofi.com/en/investors @Sanofi @Sanofi @Sanofi @SanofiaventisTVen
Social Impact
Delivering positive impact
on communities and the environment
Restoring 500 hectares
of mangroves
.Removes approx. 390 kt CO2e
.Improves water quality
and biodiversity
.Creates jobs
Sanofi is advancing towards its Net Zero target by 2050.
Two carbon offsetting programs launched with EcoAct in Kenya:
Distributing 18,250 energy-saving
biomass cookstoves
.Avoids approx. 790 kt CO2e
.Prevents deforestation
.Improves health and social conditions
of local rural families
€4,401m
Specialty Care
€3,495m
General Medicines
€1,271m
Consumer Healthcare
€3,315m
Vaccines